Literature DB >> 8881455

The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests.

H A Oomen1, A J Schipperijn, H A Drexhage.   

Abstract

OBJECTIVE: Cognitive and affective functioning is sensitive to changes in thyroid hormones. We have sought to determine: (1) the prevalence of thyroid function abnormalities in a psychiatric population on admission (as compared to the prevalence in a normal population), and (2) whether such thyroid function abnormalities are associated with the occurrence or development of cognitive and affective disorders.
DESIGN: Serum was collected 2-3 weeks after hospitalization in 3 major clinics from 3756 psychiatric patients in 1987-1990, stored, and assayed in 1993 for the presence of antibodies against the TSH-receptor and thyroperoxidase (TPO-Ab) and for TSH levels. The psychiatric cohort was matched with a control population of healthy individuals living in the same area (n = 1877). The prevalence study was followed by a case-control study involving patients from one clinic that had routinely assigned a DSM-IIIR classification to its patients. Cases were those admissions with thyroid abnormalities and three subgroups of cases were randomly formed demonstrating either TSH less than 0.4 mU/l (n = 44) or over 4.0 mU/l (n = 44), or TPO-Ab positivity (n = 50). Cases were compared to random controls from the same psychiatric population, viz patients without thyroid abnormalities (n = 83). Comparison was with respect to their psychiatric follow-up diagnosis (the investigator was blinded to the thyroid test results).
RESULTS: Prevalence study. The percentage of patients positive for TSH-receptor-Ab was 0.26 (9/3504), for TPO-Ab was 10.0 (331/3316) and outside the TSH range of 0.4-4.0 mU/l was 10.0 ((332/3316): 5.9% (198/3316) > 4.0 mU/l and 4.1% (134/3316) < 0.4 mU/l). Abnormal total thyroxine levels were found in only 9.8% of subjects with abnormal TSH, indicating the predominantly subclinical character of the thyroid alteration. In comparison, the healthy area controls over 55 years of age showed the same prevalence of positive TPO-antibodies and TSH under 0.4 mU/l, but a higher prevalence of TSH over 4.0 mU/l. CASE-CONTROL STUDY: In the case control analysis differences could not be noticed with regard to prevalences of dementia, schizophrenia or other psychiatric illnesses apart from the prevalence of affective disorders which were more prevalent in TPO-Ab positive patients and patients with a low serum TSH. Since prior use of lithium, carbamezapine, carbimazole and/or thyroxine could be a factor of importance in this association, analyses were also carried out excluding patients with such prior drug use. In these analyses affective disorders were still more prevalent in patients with a low serum TSH (particularly in males, 40% in cases vs 9% in controls, P < 0.05). The most significant association was however between TPO-antibody positivity (and in particular with high titre and/or with TSH > 4.0 mU/l) and a subgroup of the affective disorders, viz with a rapid cycling of bipolar disorder (18% in cases vs 0% in controls, P < 0.001).
CONCLUSION: Though causal relations cannot be determined from this cross-sectional study, this admission survey found early forms of autoimmune thyroid disease, sometimes characterized only by TPO-Abs, highly significantly associated with rapid cycles of a bipolar disorder. It also found a weak association between subclinical hyperthyroidism (low serum TSH without TPO-Ab positivity) and affective disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8881455     DOI: 10.1046/j.1365-2265.1996.d01-1558.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  16 in total

1.  Autoimmune diseases, bipolar disorder, and non-affective psychosis.

Authors:  William W Eaton; Marianne G Pedersen; Philip R Nielsen; Preben Bo Mortensen
Journal:  Bipolar Disord       Date:  2010-09       Impact factor: 6.744

Review 2.  Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research.

Authors:  Rachel L Derr; Scott J Cameron; Sherita Hill Golden
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

Review 3.  Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options.

Authors:  Robertas Bunevicius; Arthur J Prange
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Effects of hyperthyroidism, hypothyroidism, and thyroid autoimmunity on female sexual function.

Authors:  A Oppo; E Franceschi; F Atzeni; A Taberlet; S Mariotti
Journal:  J Endocrinol Invest       Date:  2011-04-28       Impact factor: 4.256

Review 5.  Thyroid hormone actions on neural cells.

Authors:  Sandra König; Vivaldo Moura Neto
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

Review 6.  Rapid cycling bipolar disorder: clinical characteristics and treatment options.

Authors:  William Coryell
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area.

Authors:  Derik Hermann; Walter Hewer; Florian Lederbogen
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

Review 8.  Subclinical hyperthyroidism: to treat or not to treat?

Authors:  E H Hoogendoorn; M den Heijer; A P J van Dijk; A R Hermus
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

9.  Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ).

Authors:  Patricia D Walshaw; Laszlo Gyulai; Michael Bauer; Mark S Bauer; Brian Calimlim; Catherine A Sugar; Peter C Whybrow
Journal:  Bipolar Disord       Date:  2018-06-04       Impact factor: 6.744

10.  Thyroid functions and bipolar affective disorder.

Authors:  Subho Chakrabarti
Journal:  J Thyroid Res       Date:  2011-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.